CGEN Berita Valas

Compugen To Receive $10 Mln Payment After Dosing First Patient In AstraZeneca's ARTEMIDE-Bil01 Trial

Cancer immunotherapy company Compugen Ltd. (CGEN) announced Monday that Compugen is entitled to receive a $10 million milestone payment from British drug major AstraZeneca (AZN), after the first patient was dosed in AstraZeneca's ARTEMIDE-Bil01 trial with rilvegostomig.

RTTNews | 581 days ago

Gilead Sciences, Compugen Ink Up To $848 Mln Deal For Pre-clinical Antibody Program

Gilead Sciences, Inc. (GILD) announced Tuesday an agreement with Holon, Israel-based cancer immunotherapy company Compugen Ltd. (CGEN) to exclusively license its potential first-in-class, pre-clinical antibody program against IL-18 binding protein, including the COM503 drug candidate.

RTTNews | 601 days ago

Terms | Privacy | Site Map | Site Map Calendar

HIGH RISK WARNING: Foreign exchange trading carries a high level of risk that may not be suitable for all investors. Leverage creates additional risk and loss exposure. Before you decide to trade foreign exchange, carefully consider your investment objectives, experience level, and risk tolerance. You could lose some or all of your initial investment. Do not invest money that you cannot afford to lose. Educate yourself on the risks associated with foreign exchange trading, and seek advice from an independent financial or tax advisor if you have any questions. Any data and information is provided 'as is' solely for informational purposes, and is not intended for trading purposes or advice. Past performance is not indicative of future results.

EURUSD	1.16091	GBPUSD	1.34293	AUDUSD	0.65132
USDJPY	148.018	USDCAD	1.37817	USDCHF	0.81246